Methylphenidate vs Amphetamine: Choosing an ADHD Stimulant Class

Methylphenidate and amphetamine are the two families of stimulant medication for ADHD. A large comparison of ADHD drugs, a 2018 network meta-analysis in Lancet Psychiatry, concluded that methylphenidate is the preferred first choice for children and adolescents and amphetamines for adults, taking both effectiveness and tolerability into account. That is a starting point, not a rule: individual response is unpredictable, and the American Academy of Pediatrics notes that about 40% of children respond to both families and about 40% respond to only one.

So the practical answer is to start with the family that best fits your age, health history and daily schedule, give it a fair trial, and switch families if it does not work or is not tolerated. That decision, and every dose change, belongs with your prescriber.

The two families at a glance

How they differ in the brain

Both families raise the activity of dopamine and norepinephrine, but not in the same way. The methylphenidate label describes it as blocking the reuptake of norepinephrine and dopamine into nerve cells and increasing their release. Amphetamine labels describe amphetamines as sympathomimetic amines with central nervous system stimulant activity. Both labels state plainly that the exact way these drugs improve ADHD is not known.

Methylphenidate is a mixture of two mirror-image forms, and the d-form is the more active one. Dexmethylphenidate (Focalin) contains only that d-form, which is why its doses are lower than those of standard methylphenidate. Mixed amphetamine salts (Adderall) contain dextroamphetamine and levoamphetamine in a 3:1 ratio, while lisdexamfetamine (Vyvanse) is converted in the body to dextroamphetamine alone. These differences explain why someone can feel quite different on two drugs from the same family, not only across families.

What the evidence shows

The 2018 analysis by Cortese and colleagues pooled 133 double-blind randomized trials: 81 in children and adolescents, 51 in adults and one in both. Its main findings on the two stimulant families:

A larger negative number means a bigger reduction in symptoms. In head-to-head comparisons, the analysis found amphetamines more effective than methylphenidate on clinician ratings in both age groups, but in children amphetamines, unlike methylphenidate, led to more side-effect dropouts than placebo, and weighing efficacy and tolerability together the authors favored methylphenidate for that age group.

Three limits matter. The analysis covered short-term treatment, closest to 12 weeks, and found too little data to judge effects at 26 or 52 weeks. Confidence in many of the indirect comparisons was rated low or very low. And averages across thousands of people do not predict your own response, which is the point the AAP makes about the roughly 40% who respond to only one family. The AAP also notes that ADHD subtype does not appear to predict response to a specific drug.

What the guidelines recommend

For children and young people aged 5 and older, NICE recommends methylphenidate as the first medication, with a switch to lisdexamfetamine considered after a 6-week trial of methylphenidate at an adequate dose that has not helped enough. For adults, NICE offers lisdexamfetamine or methylphenidate as first-line options and suggests switching to the other after a 6-week trial that has not helped enough. It recommends a second opinion or specialist referral if symptoms have not responded to one or more stimulants and one non-stimulant.

The AAP's 2019 guideline for children and adolescents describes the evidence as particularly strong for stimulants as a group, and it states that the effect size is about 1.0 for stimulants compared with about 0.7 for non-stimulants. For school-age children it recommends FDA-approved ADHD medication without ranking one stimulant family above the other, although for preschool children it names methylphenidate as the recommended first medication. Families should expect a discussion rather than a fixed rule. Age-specific choices are covered in child psychiatrist vs pediatrician for ADHD and parent training for child ADHD.

Side effects: more similar than different

Because both families stimulate the same systems, their labels share most warnings: risks for people with serious heart disease, increases in blood pressure and heart rate, possible psychiatric effects including mania in people at risk, slowed growth in children, circulation problems in the fingers and toes, and the boxed warning on misuse. Both labels direct the prescriber to check for tics or Tourette's syndrome before starting.

These are the most common adverse reactions reported in each label's adult trials, not a direct head-to-head comparison. In the meta-analysis, amphetamines led to more side-effect dropouts than placebo in both children and adults, while methylphenidate did so only in adults. Individual differences dominate: some people find one family makes them irritable or flat and the other does not.

Heart and blood pressure checks apply to both; see ADHD medication and your heart.

Formulations often matter more than the family

Within each family there are short-acting tablets, long-acting capsules and tablets, and non-pill options. The formulation often decides how well a medication fits a workday or school day.

• Short-acting methylphenidate (Ritalin) is taken two or three times a day.
• Concerta, a once-daily methylphenidate tablet, showed improvements in children's attention and behavior that were maintained through 12 hours after dosing.
• The Daytrana methylphenidate patch is worn on the hip for up to 9 hours, is approved for ages 6 to 17, and can be removed early to shorten the effect.
• Vyvanse improved adults' attention at every time point measured from 2 to 14 hours after the dose.
• The Xelstrym dextroamphetamine patch is approved for adults and children 6 and older.
• Dyanavel XR comes as an extended-release amphetamine liquid or tablet for patients 6 and older.

The methylphenidate options are compared in detail in Concerta vs Ritalin vs Focalin, and the two best-known amphetamine products in Adderall vs Vyvanse.

Supply problems can force the choice

Shortages have affected both families. When checked on 26 October 2026, the FDA drug shortage database listed methylphenidate extended-release tablets (the Concerta type), the methylphenidate patch, immediate-release mixed amphetamine salts tablets, and lisdexamfetamine capsules and chewable tablets as current shortages. Availability varies by manufacturer and strength. If your pharmacy cannot fill a prescription, a prescriber may change the strength, the manufacturer, the formulation or the family; see what to do during a stimulant shortage.

Special situations

Young children

For children aged 4 to their sixth birthday, the AAP recommends parent training in behavior management and/or behavioral classroom interventions first, and says methylphenidate may be considered if those do not bring significant improvement and moderate-to-severe problems continue. FDA labeling does not line up neatly with that advice: methylphenidate products such as Ritalin and Concerta are labeled for ages 6 and older, while immediate-release Adderall's label includes dosing from age 3. The Vyvanse label says it is not recommended under 6 because younger children had higher drug levels and more side effects, such as weight loss. Choices in this age group belong with a pediatric specialist; see parent training for child ADHD.

Tics, autism and anxiety

NICE recommends offering people with ADHD and an anxiety disorder, a tic disorder or autism the same medication choices as anyone else with ADHD. Both stimulant labels still ask prescribers to check for tics and Tourette's syndrome before starting and to watch for new or worsening tics.

Mania or psychosis

NICE advises stopping ADHD medication during an acute psychotic or manic episode and considering restarting only after it resolves. Amphetamine labels direct prescribers to screen for risk factors for a manic episode before starting, such as a history of depressive symptoms or a family history of suicide, bipolar disorder or depression.

What the evidence does not tell you

It helps to be clear about the gaps, because confident claims online often go beyond the data.

• Long-term comparisons are thin. The 2018 meta-analysis could not compare the families at 26 or 52 weeks because there was too little data.
• There is no reliable predictor of who will respond to which family. The AAP notes that ADHD subtype does not appear to predict response.
• Genetic tests do not pick the stimulant for you. The AAP states that current pharmacogenetic tools lack sufficient evidence of clinical usefulness and does not recommend them. More detail is in pharmacogenomic testing and its limits.
• Group averages do not settle an individual choice. Because response is so individual, guidelines describe a structured trial of one family, then the other if needed.

Switching from one family to the other

A switch is not a failure; it is often the plan. NICE builds it into the pathway for both children and adults, after a 6-week trial at an adequate dose that has not helped enough. Because doses are not interchangeable across families, the new medication is usually started at its own starting dose and adjusted step by step rather than converted milligram for milligram; the Adderall XR label, for example, gives a single recommended adult dose for people switching from another medication. Within the methylphenidate family, some conversions are written into labels; for example, the Focalin label starts people already on methylphenidate at half their total daily methylphenidate dose.

Bring notes to the switch visit: what helped, what did not, when the dose seemed to wear off, and any side effects. If one or more stimulants and a non-stimulant have not worked, NICE suggests a second opinion or a specialist referral, and the guide to a psychiatric medication second opinion explains what that involves. The practice's article on when ADHD medication stops working covers problems that can mimic a failed trial, such as sleep loss or timing.

How a prescriber usually decides, and what to ask

A reasonable decision weighs several factors at once. These are worth raising at the visit:

1. Your age, and what the guidelines suggest for it.
2. Any past response to either family, including side effects you had.
3. How many hours of coverage you need, and whether evening sleep is already fragile.
4. Heart history, blood pressure, and any personal or family history of bipolar disorder, tics or substance use.
5. Whether you can swallow pills, or need a liquid, chewable or patch.
6. What your pharmacy can supply and what your insurance covers.
7. How long the first trial will last before you decide together; NICE uses 6 weeks at an adequate dose.

Stimulant labels describe starting at a set dose and adjusting it at weekly intervals according to response and tolerability; the practice's article on low-dose ADHD medication explains why. If neither stimulant family works or is tolerated, non-stimulants are covered in stimulant vs non-stimulant ADHD medication and Qelbree vs Strattera. Do not swap families, change doses or share medication on your own.

How Dr. Lewis's team approaches ADHD treatment

The practice's ADHD assessment, for children and adults in person or by telehealth, uses a structured clinical interview, rating scales that support but do not replace clinical diagnosis, and collateral history, followed by a written summary and treatment plan. Plans may include lifestyle changes, nutrition, psychotherapy, executive-function coaching, and medications when appropriate, and ongoing medication management is part of the practice's care. More is on the ADHD assessment page and the adult ADHD page. For other decisions about care, see the choosing psychiatric care guide.

Frequently asked questions

If Adderall did not work for me, will Ritalin or Concerta?

Possibly. The American Academy of Pediatrics notes that about 40% of children respond to only one of the two families, so a poor response to one does not rule out the other. Your prescriber can judge whether the first trial was long enough and at an adequate dose.

Is amphetamine stronger than methylphenidate?

On average, the 2018 meta-analysis found a larger effect for amphetamines on clinician-rated symptoms, but also more people stopping because of side effects. Averages do not predict your own response, and doses of the two families are not interchangeable.

Which stimulant is better for anxiety?

NICE recommends offering people with ADHD and an anxiety disorder the same medication choices as other people with ADHD, so anxiety alone does not decide the family. How the two conditions are sequenced is discussed in ADHD and anxiety: which to treat first.

Are there stimulants that are not pills?

Yes. There is a methylphenidate patch (Daytrana) for ages 6 to 17, a dextroamphetamine patch (Xelstrym) for adults and children 6 and older, an amphetamine liquid, and several chewable or orally disintegrating tablets. Some have been affected by shortages.

How long should I try one family before switching?

NICE suggests a 6-week trial at an adequate dose before deciding it has not helped enough. Your prescriber may adjust earlier if side effects are a problem.

Is one family safer for the heart?

Both carry the same heart-related warnings and require screening and blood pressure monitoring. The choice between them is not usually made on heart risk alone.

Sources

1. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738 (Cortese S et al.), PubMed 30097390, 2018. pubmed.ncbi.nlm.nih.gov
2. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. American Academy of Pediatrics, Pediatrics 144(4):e20192528, 2019. pmc.ncbi.nlm.nih.gov
3. Attention deficit hyperactivity disorder: diagnosis and management (NG87), Recommendations. National Institute for Health and Care Excellence, 2019. nice.org.uk
4. Concerta (methylphenidate HCl) extended-release tablets prescribing information. Janssen Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
5. Ritalin (methylphenidate hydrochloride) tablets prescribing information. Sandoz / DailyMed (NLM), 2023. dailymed.nlm.nih.gov
6. Adderall XR (mixed salts of a single-entity amphetamine product) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
7. Vyvanse (lisdexamfetamine dimesylate) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
8. Daytrana (methylphenidate transdermal system) prescribing information. Noven Therapeutics / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
9. Xelstrym (dextroamphetamine) transdermal system prescribing information. Noven Therapeutics / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
10. 21 CFR 1308.12 Schedule II. Electronic Code of Federal Regulations (DEA), 2026. ecfr.gov
11. FDA Drug Shortages Database: methylphenidate ER tablets and transdermal film; amphetamine mixed salts tablets; lisdexamfetamine. U.S. Food and Drug Administration, 2026. dps.fda.gov
12. Focalin (dexmethylphenidate hydrochloride) tablets prescribing information. Sandoz / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
13. Dyanavel XR (amphetamine) extended-release oral suspension and tablets prescribing information. Tris Pharma (NextWave Pharmaceuticals) / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
14. QuilliChew ER (methylphenidate HCl) extended-release chewable tablets prescribing information. Tris Pharma (NextWave Pharmaceuticals) / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
15. Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets prescribing information. Neos Therapeutics / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
16. Adderall (mixed amphetamine salts) tablets prescribing information. Teva Pharmaceuticals / DailyMed (NLM), 2024. dailymed.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.